Protocol Ledger

NCT04854096 · Phase II · TERMINATED

Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

Interventional Phase II clinical trial protocol NCT04854096 sponsored by NS Pharma in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-01-31 Enrollment: 7 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04854096
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)7 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04854096
Protocol FieldVerified Registry Value
NCT IdentifierNCT04854096
Consolidated Lead SponsorNS Pharma
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment7 participants (ACTUAL)
Registered Start Date2023-01-31
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04854096
Hospital Research SiteLocationSite Profile
Houston Methodist HospitalHouston, TXOpen Hospital Dossier ->
MD Anderson Cancer CenterHouston, TXOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI